We help international patients access GC101 TIL cell therapy clinical trials in China — with free eligibility screening and personalized guidance.
CancerPath was founded to bridge the information gap between Chinese clinical research in TIL cell therapy and international patients who may benefit from it. We believe that geographic boundaries should not prevent patients from accessing potentially life-saving treatments.
China is one of the most advanced countries in the world for cell therapy clinical trials. However, for English-speaking patients abroad, navigating the Chinese healthcare system, understanding clinical trial eligibility, and coordinating treatment logistics can be overwhelming. CancerPath exists to make this process accessible, transparent, and stress-free.
Free service: Our initial eligibility assessment is always free. We do not charge patients for reviewing medical records, answering questions, or providing guidance about TIL therapy options.
CancerPath works closely with the leading oncology investigators in China who lead GC101 and GC203 clinical trials. Our network includes:
Every recommendation we make is guided by what is best for the patient, not by commercial interests.
We provide clear, complete information about treatment options, costs, risks, and expected outcomes.
Our guidance is based on published clinical data and direct communication with principal investigators.
We navigate language, cultural, and healthcare system differences so you can focus on treatment.
Ready to explore whether GC101 TIL therapy is right for you? Start with a free eligibility assessment by emailing us your medical records.
Email: clinicaltrials@juncell.com
Response time: We respond to all enquiries within 48 hours.
Languages: English, Chinese